is no TRANSFORM: A Randomized, seen seen criteria Doubleblind, Multicenter, Active-controlled pre-screen Study to Evaluate the Efficacy, Safety, and records. 91 No Tolerability of Intranasal Esketamine Plus No Approval many patients patients Neither an Oral Antidepressant in Elderly Subjects 100340 181387 exclusion 15/sc/0432 16/06/2015 05/10/2016 15/06/2016 12/10/2016 04/01/2017 04/01/2017 in clinical with Treatment-resistant Depression No HRA of - F eligible fails resulting inclusion of SUSTAIN-2 3004: An Open-label, no in is seen Safety and Efficacy Study of No trial patients Intranasal Esketamine in No Approval seen Neither clinical eligible Depression No 100341 181955 many exclusion criteria inclusion 15/sc/0434 18/10/2016 - resulting records. patients HRA F Multi Centre RCT of a group psychOlogical off to over intervention for poStnatal depression in date No - due sign britisH mothers of south asiaN origIn - H Approval illness. delays Neither ROSHNI-2 100342 187851 Yes- christmas Contracting unavailable 05/01/2017 16/nw/0727 staff NIHR break delayed HRA as sites has from the Speech and language -phase 1 survey No has any Other No HRA its were and been allocated - to 100343 188072 and Sponsor Approval deemed J such consents study 12/12/2016 16/nw/0500 recruitment not exempt specific A pilot study to test the feasibility and acceptability of delivering recovery focused 30 Yes cognitive-behavioural therapy to older Approval Yes adults with bipolar disorder 100344 163066 17/02/2017 18/01/2017 15/nw/0330 HRA GOTHIC1: A feasibility trial of glycopyrrolate in comparison to hyoscine 18 24 42 Yes 100387 hydrobromide and placebo in the treatment Yes Approval of clozapine-induced hypersalivation 172540 09/08/2016 15/nw/0823 09/03/2017 01/06/2015 26/01/2017 26/01/2017 13/02/2017 13/02/2017 HRA
100340 15/sc/0432 181387 HRA Approval TRANSFORM: A Randomized, Doubleblind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatment-resistant Depression No 91 No 16/06/2015 05/10/2016 15/06/2016 12/10/2016 04/01/2017 04/01/2017 F - No patients seen inclusion exclusion criteria is resulting in many pre-screen fails of clinical records. no eligible patients seen Neither 100341 15/sc/0434 181955 HRA Approval SUSTAIN-2 3004: An Open-label, Safety and Efficacy Study of Intranasal Esketamine in Depression No No 18/10/2016 F - No patients seen inclusion exclusion criteria is resulting in many of clinical records. no eligible patients seen Neither 100342 16/nw/0727 187851 HRA Approval Multi Centre RCT of a group psychOlogical intervention for poStnatal depression in britisH mothers of south asiaN origIn - ROSHNI-2 Yes- date unavailable No 05/01/2017 H - Contracting delays NIHR sign off delayed over christmas break due to staff illness. Neither 100343 16/nw/0500 188072 HRA Approval Speech and language -phase 1 survey No No 12/12/2016 J - Other consents were and as such the study has not allocated recruitment to any specific sites and has been deemed exempt from its Sponsor 100344 15/nw/0330 163066 HRA Approval A pilot study to test the feasibility and acceptability of delivering recovery focused cognitive-behavioural therapy to older adults with bipolar disorder Yes 17/02/2017 30 Yes 18/01/2017 100387 15/nw/0823 172540 HRA Approval GOTHIC1: A feasibility trial of glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of clozapine-induced hypersalivation Yes 09/03/2017 18 24 42 Yes 01/06/2015 26/01/2017 09/08/2016 26/01/2017 13/02/2017 13/02/2017 trial
Performance%20in%20Initiating%20Research%20-%20Q1%202017-18.docx